Research and Markets: Study Analysis of the RLS Market IMS Sales Data from 2004 to 2007 for Major on- and off-Label Marketed Restless Legs Syndrome Drugs

2008-12-17 13:52:02 -

Research and Markets (www.researchandmarkets.com/research/da788e/restless_legs_synd) has announced the addition of the "Restless Legs Syndrome - Novel Drugs to Prosper as Lifecycle Management Strategies Fail" report to their offering.
Restless legs syndrome (RLS) is a neurological condition, which affects 15.5 million medically significant sufferers across the seven major markets (7MM). Through Requip (ropinirole) and Mirapex's (pramipexole) regulatory approvals in 2005-06, GlaxoSmithKline and Boehringer Ingelheim pioneered the on-label RLS market, which reached $588m in 2007 across the 7MM.
Scope
- Patient potential including disease definition, etiology, patient segmentation, prevalence, presentation, diagnosis, and treatment guideline review.
- Review of the key unmet needs in the treatment of restless legs syndrome as identified by key opinion leaders for the report.
- Analysis of the RLS market IMS sales data from 2004 to 2007 for major on- and off-label marketed restless legs syndrome drugs.
- Pipeline analysis with detailed profiles for key late-stage drugs: Neupro (rotigotine patch), Nenad (lisuride patch), Solzira (gabapentin enacarbil).
Highlights
Inappropriate pharmacokinetic properties may limit the development of oral extended-release versions of the current oral brands for restless legs syndrome, and prevent off-label prescribing of formulations designed with optimal pharmacokinetics for Parkinson's disease.
Drugs acting with a different mechanism and inducing no augmentation could become beneficial alternatives to current dopamine agonists. Solzira is expected to become a leading brand in the future market as specialists and primary care physicians may be more confident to prescribe it to a larger population and particularly to mild patients.
Drugs with new delivery methods could be helpful for RLS patients and prove commercially successful. While formulations with a long duration of action (e.g. UCB's Neupro) may be beneficial for severe patients, treatments with rapid onset of action (e.g. UCB's rotigotine nasal spray) could be used as rescue therapy in moderate-to-severe patients.
Reasons to Purchase
- Quantify the RLS market value in the US, 5EU and Japan and identify the drivers and resistors for RLS treatments.
- Understand key opinion leader (KOL) views on topical issues in the current and future treatment of RLS symptoms.
- Explore the R&D pipeline for RLS and the future directions of the market as identified by interviewed KOLs.
Key Topics Covered:
- CHAPTER 1 EXECUTIVE SUMMARY
- CHAPTER 2 DEFINITION OF MOLECULAR DIAGNOSTICS
- CHAPTER 3 REGULATORY AND DEVELOPMENT PATHWAY
- CHAPTER 4 THE MOLECULAR DIAGNOSTIC MARKET
- CHAPTER 5 THE KEY MOLECULAR DIAGNOSTIC TESTS
- CHAPTER 6 APPENDIX
- List of Tables
Companies Mentioned:
- Invitrogen
- Ventana
- Abbott
- Siemens
- Dako
- DxS
- Genzyme Genetic
- TrimGen
- Roche
- bioMerieux
- Qiagen
- Myriad
- Cytocell
- American Diagnostica
For more information visit www.researchandmarkets.com/research/da788e/restless_legs_synd
Source: Datamonitor


Laura Wood

Senior Manager

press@researchandmarkets.com

Fax from USA: 646-607-1907

Fax from rest of the world: +353-1-481-1716